Two years after two new drugs to treat tuberculosis—the first in over 50 years—were conditionally approved for use, only 2% of the 150,000 people who need them have been able to access them, according to Médecins Sans Frontières (MSF). MSF and other treatment providers are showing that stronger TB...
Médecins Sans Frontières/Doctors Without Borders (MSF) has filed a ‘patent opposition’ in India to prevent US pharmaceutical company Pfizer from getting a patent on the pneumococcal conjugate vaccine (PCV13), so more affordable versions can become available to developing countries and humanitarian...
More than two years after drug approved, only 180 people globally have received it. Geneva, 24 February 2016 Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it...
Ministerial Conference on Immunisation in Africa presses countries to do more, but gives free pass to pharmaceutical companies charging inflated vaccine prices. As the first-ever Ministerial-level meeting on immunisation in Africa gets underway today, the international medical humanitarian...
As representatives from the United States and 11 other Pacific-Rim countries gather in New Zealand today to sign the Trans-Pacific Partnership (TPP) trade agreement, the fight to protect access to medicines in TPP countries is intensifying at the national level, with legislative processes starting...
MSF Asks Supporters in Southeast Asia to TURN RED for more affordable pneumonia vaccine Hong Kong/Jakarta, 12 November 2015—The international medical humanitarian organisation Médecins Sans Frontières/Doctors Without Borders (MSF) launched ‘A Fair Shot’ online campaign today on World Pneumonia Day...
The clock is ticking. Asian countries are under time pressure to sacrifice public health interests to get final agreement on a trade deal. The Trans-Pacific Partnership (TPP), which is currently being negotiated between the US and 11 other Pacific Rim nations – including Malaysia, Singapore, Brunei...
Médecins Sans Frontières (MSF) response to the news MSF has learned that the Chinese patent office has just denied Gilead Science’s request for a key patent on the hepatitis C drug sofosbuvir. This drug, together with other antivirals, is the backbone of several newer, more effective curative...
Resolution passes at World Health Assembly, calling for more affordable vaccines and greater transparency on vaccine pricing Governments meeting in Geneva for the annual World Health Assembly raised the alarm today on the exorbitant rise in the price to vaccinate a child, and took a decisive step...
Indian generic companies should reject Gilead’s controversial hepatitis C programme Programme could compromise patient treatment and privacy rights Ahead of a meeting in Jaipur, India this week between US pharmaceutical company Gilead Sciences and several Indian companies which have entered into an...
